Streamlining Rheumatology TMS / Ketamine Prior Auth Workflows

Klivira provides advanced automation to navigate the complexities of rheumatology TMS / ketamine prior auth, ensuring timely access to critical mental health treatments for patients with co-morbid conditions.

Rheumatology patients, often managing chronic inflammatory conditions with high-cost biologics, frequently experience co-morbid depression. Integrating prior authorization for specialized mental health interventions like TMS and esketamine (Spravato) into an already burdened rheumatology PA workflow presents unique challenges. Klivira's platform is engineered to address this dual complexity, harmonizing distinct clinical and administrative requirements.

The Dual Challenge: Rheumatology Biologics and Advanced Mental Health Therapies

Rheumatology practices face a significant prior authorization burden from biologics, JAK inhibitors, and infusion therapies, which require extensive documentation aligned with ACR Treatment Guidelines. Introducing high-cost, specialized mental health treatments like TMS and esketamine adds another layer of administrative complexity. Managing these diverse PA requirements for the same patient demands a unified, intelligent approach to prevent delays in care.

Key Prior Authorization Triggers for Rheumatology Patients Undergoing TMS/Ketamine

Biologic therapies (e.g., Humira, Enbrel, Stelara, Skyrizi, Rinvoq) for underlying rheumatologic conditions.
JAK inhibitors (e.g., tofacitinib, baricitinib, upadacitinib) with specific cardiovascular and thrombosis risk considerations.
Transcranial Magnetic Stimulation (TMS) procedures for treatment-resistant depression.
Esketamine (Spravato) prescriptions, often requiring REMS program compliance and prior treatment documentation.
Advanced imaging (e.g., MRI) for inflammatory arthritis assessment, potentially overlapping with mental health diagnostics.
Ongoing re-authorizations for chronic rheumatologic treatments, alongside new mental health PA submissions.

Navigating Complex Documentation for Rheumatology TMS / Ketamine Prior Auth

Successful prior authorization for rheumatology patients receiving TMS or ketamine requires meticulous documentation that satisfies both clinical domains. For rheumatology, this includes ICD-10 with disease-specific criteria (e.g., 2010 ACR/EULAR for RA), disease activity scores (DAS28, CDAI), prior DMARD trials, and screening completion (TB, hepatitis). For TMS/ketamine, documentation of prior treatment failures for depression and adherence to specific program requirements like Spravato REMS are paramount.

Common Prior Authorization Denial Points for Co-Morbid Care

Failure to document specific prior conventional DMARD trials or step therapy compliance for rheumatologic biologics.
Missing or insufficient documentation of prior antidepressant treatment failures for TMS or esketamine.
Incomplete disease activity assessment (e.g., DAS28, PASI) for rheumatology or symptom severity scales for mental health.
Gaps in screening documentation (TB, hepatitis) prior to immunosuppressive biologic initiation.
Non-compliance with Spravato REMS program requirements or other payer-specific criteria for advanced mental health therapies.
Biosimilar substitution mandates for rheumatology biologics not addressed, impacting overall patient care continuity.

Klivira's Intelligent Automation for Rheumatology TMS / Ketamine Prior Auth

Klivira's platform provides a cohesive solution for managing the intricate prior authorization landscape of rheumatology patients requiring TMS or ketamine. Our system integrates with EMRs to extract relevant clinical data, applies ACR-guideline-aware policy logic for rheumatology treatments, and streamlines documentation for advanced mental health therapies. This comprehensive approach minimizes manual effort, reduces denial rates, and accelerates patient access to care across both specialties.

Unified Workflow for Enhanced Patient Access

By automating the medical benefit and pharmacy benefit PA processes, Klivira ensures that both provider-administered infusions and self-administered injections for rheumatology, alongside TMS procedures and esketamine prescriptions, are handled efficiently. Our system accounts for biosimilar substitution policies and periodic re-authorization workflows, providing a consistent and evidence-grounded approach to PA submission for this complex patient cohort.

Frequently asked questions

How does Klivira handle the different documentation requirements for rheumatology biologics and TMS/Ketamine?

Klivira's intelligent platform is designed to recognize and extract the distinct documentation required for each therapy type. For rheumatology, it leverages ACR-guideline-aware logic for criteria like disease activity scores and step therapy. For TMS/ketamine, it focuses on prior treatment failures and specific program requirements like Spravato REMS, ensuring all necessary data points are captured and submitted.

Can Klivira integrate with both our EMR and mental health-specific platforms for these PAs?

Yes, Klivira offers robust integration capabilities, including SMART on FHIR, to connect with various EMR systems. This allows for seamless data flow from patient records, consolidating information required for both rheumatology and mental health prior authorizations into a single, automated workflow, regardless of disparate source systems.

What are the common challenges in getting TMS/Ketamine approved for rheumatology patients?

Key challenges include documenting prior treatment failures for depression while simultaneously managing complex rheumatology PA requirements. Payers often have stringent criteria for these advanced mental health therapies, which, when combined with the existing burden of biologic PAs, can lead to increased administrative overhead and potential delays if not managed efficiently.

How does Klivira manage re-authorizations for chronic rheumatology treatments alongside new TMS/Ketamine PAs?

Klivira's platform includes a dedicated periodic re-authorization workflow for chronic treatments, common in rheumatology. This system runs in parallel with new PA submissions for TMS/ketamine, intelligently prioritizing and managing both. It ensures continuous documentation of disease response for re-auths while also facilitating the initial and subsequent PAs for mental health interventions.

Does Klivira account for step therapy requirements for both rheumatology biologics and TMS/Ketamine?

Absolutely. Klivira's policy engine incorporates payer-specific step therapy rules for both rheumatology biologics and advanced mental health treatments. This includes mandates for biosimilar substitution in rheumatology and documentation of prior antidepressant trials for TMS/ketamine, ensuring compliance with payer guidelines and reducing denial risks.